Royalty Pharma (RPRX) Total Debt (2019 - 2026)

Royalty Pharma has disclosed Total Debt across 8 years of filings, most recently posting $9.0 billion for Q1 2026.

• Total Debt for Q1 2026 came in at $9.0 billion, up 17.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.0 billion (up 17.58% YoY), and the FY2025 annual result was $9.0 billion, up 17.58% from the prior year.
• Total Debt came in at $9.0 billion for Q1 2026 at Royalty Pharma, roughly flat from $9.0 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $9.0 billion in Q1 2026 to a low of $6.1 billion in Q3 2023.
• The 5-year median for Total Debt is $7.2 billion (2022), against an average of $7.3 billion.
• Across the five-year window, Total Debt slipped 13.8% in 2023 and grew 24.08% in 2024, its largest moves.
• Royalty Pharma's Total Debt stood at $7.1 billion in 2022, then retreated by 13.79% to $6.1 billion in 2023, then increased by 24.08% to $7.6 billion in 2024, then climbed by 17.58% to $9.0 billion in 2025, then climbed by 0.06% to $9.0 billion in 2026.
• The last three Total Debt figures came in at $9.0 billion (Q1 2026), $9.0 billion (Q4 2025), and $8.9 billion (Q3 2025), per Business Quant data.